Molecular Imaging and Therapy Laboratory, Vrije Universiteit Brussel, Brussels, Belgium.
Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Fontenay-aux-Roses & Le Kremlin-Bicêtre, Inserm, Paris, CEA, France.
Eur J Nucl Med Mol Imaging. 2024 Dec;52(1):193-207. doi: 10.1007/s00259-024-06896-3. Epub 2024 Sep 2.
While immunotherapy has revolutionized the oncology field, variations in therapy responsiveness limit the broad applicability of these therapies. Diagnostic imaging of immune cell, and specifically CD8 T cell, dynamics could allow early patient stratification and result in improved therapy efficacy and safety. In this study, we report the development of a nanobody-based immunotracer for non-invasive SPECT and PET imaging of human CD8 T-cell dynamics.
Nanobodies targeting human CD8β were generated by llama immunizations and subsequent biopanning. The lead anti-human CD8β nanobody was characterized on binding, specificity, stability and toxicity. The lead nanobody was labeled with technetium-99m, gallium-68 and copper-64 for non-invasive imaging of human T-cell lymphomas and CD8 T cells in human CD8 transgenic mice and non-human primates by SPECT/CT or PET/CT. Repeated imaging of CD8 T cells in MC38 tumor-bearing mice allowed visualization of CD8 T-cell dynamics.
The nanobody-based immunotracer showed high affinity and specific binding to human CD8 without unwanted immune activation. CD8 T cells were non-invasively visualized by SPECT and PET imaging in naïve and tumor-bearing mice and in naïve non-human primates with high sensitivity. The nanobody-based immunotracer showed enhanced specificity for CD8 T cells and/or faster in vivo pharmacokinetics compared to previous human CD8-targeting immunotracers, allowing us to follow human CD8 T-cell dynamics already at early timepoints.
This study describes the development of a more specific human CD8 T-cell-targeting immunotracer, allowing follow-up of immunotherapy responses by non-invasive imaging of human CD8 T-cell dynamics.
虽然免疫疗法已经彻底改变了肿瘤学领域,但治疗反应的变化限制了这些疗法的广泛适用性。免疫细胞,特别是 CD8 T 细胞的动态的诊断成像可以实现早期患者分层,并提高治疗效果和安全性。在这项研究中,我们报告了一种基于纳米体的免疫示踪剂的开发,用于非侵入性 SPECT 和 PET 成像人类 CD8 T 细胞的动力学。
通过骆驼科动物免疫和随后的生物淘选产生针对人 CD8β的纳米体。针对人 CD8β的先导抗纳米体在结合、特异性、稳定性和毒性方面进行了表征。将先导纳米体用锝-99m、镓-68 和铜-64 标记,用于 SPECT/CT 或 PET/CT 对人类 CD8 转基因小鼠和非人类灵长类动物中的人类 T 细胞淋巴瘤和 CD8 T 细胞进行非侵入性成像。对 MC38 荷瘤小鼠中 CD8 T 细胞的重复成像允许可视化 CD8 T 细胞的动力学。
基于纳米体的免疫示踪剂与人 CD8 具有高亲和力和特异性结合,而不会引起不必要的免疫激活。在未受感染和荷瘤小鼠以及未受感染的非人类灵长类动物中,通过 SPECT 和 PET 成像可非侵入性地可视化 CD8 T 细胞,具有很高的灵敏度。与以前的靶向人 CD8 的免疫示踪剂相比,基于纳米体的免疫示踪剂对 CD8 T 细胞具有更高的特异性,或者体内药代动力学更快,使我们能够在早期时间点就跟踪人 CD8 T 细胞的动力学。
本研究描述了一种更特异的靶向人 CD8 T 细胞的免疫示踪剂的开发,允许通过非侵入性成像跟踪人 CD8 T 细胞的动力学来监测免疫治疗反应。